ZYMEWORKS
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune, and inflammatory diseases. Zymeworks' approach combines proprietary molecular modeling and simulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization. It was founded in 2004 and headquartered in Vancouver, British Columbia.
ZYMEWORKS
Industry:
Biotechnology Medical Therapeutics
Founded:
2004-04-01
Address:
Vancouver, British Columbia, Canada
Country:
Canada
Website Url:
http://www.zymeworks.com
Total Employee:
251+
Status:
Active
Contact:
(604)678-1388
Email Addresses:
[email protected]
Total Funding:
883.66 M USD
Technology used in webpage:
Domain Not Resolving Mobile Non Scaleable Content BootstrapCDN ReCAPTCHA V2 Microsoft Gravity Forms Java EE Amazon Oregon Region Amazon Elastic Load Balancing Akamai Hosted
Similar Organizations
1859
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics.
Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Kymera Therapeutics
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Magenta Therapeutics
Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-03-22 | Kairos Therapeutics | Kairos Therapeutics acquired by Zymeworks | N/A |
Investors List
EcoR1 Capital
EcoR1 Capital investment in Post-IPO Equity - Zymeworks
Business Development Bank of Canada
Business Development Bank of Canada investment in Post-IPO Equity - Zymeworks
Amplitude Venture Capital
Amplitude Venture Capital investment in Post-IPO Equity - Zymeworks
Wells Fargo Securities Canada
Wells Fargo Securities Canada investment in Post-IPO Equity - Zymeworks
Raymond James
Raymond James investment in Post-IPO Equity - Zymeworks
Paradigm Capital
Paradigm Capital investment in Post-IPO Equity - Zymeworks
Citigroup Global Markets Canada Inc
Citigroup Global Markets Canada Inc investment in Post-IPO Equity - Zymeworks
MTS Health Partners
MTS Health Partners investment in Post-IPO Equity - Zymeworks
Fonds de solidarité FTQ
Fonds de solidarité FTQ investment in Series A - Zymeworks
Northleaf Capital Partners
Northleaf Capital Partners investment in Series A - Zymeworks
Key Employee Changes
Official Site Inspections
http://www.zymeworks.com Semrush global rank: 2.65 M Semrush visits lastest month: 6.63 K
- Host name: 23.185.0.4
- IP address: 23.185.0.4
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Zymeworks"
Who We Are - Zymeworks
Who We Are Zymeworks is a global biotechnology company developing novel, multifunctional therapeutics to address difficult-to-treat diseases. We are driven by our mission to make a …See details»
Zymeworks - Wikipedia
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and …See details»
Zymeworks - Crunchbase Company Profile & Funding
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is …See details»
Investor Relations | Zymeworks Inc.
Mar 11, 2025 Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 VANCOUVER, British Columbia , April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical …See details»
Zymeworks Inc. - LinkedIn
Zymeworks Inc. | 30,205 followers on LinkedIn. Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases. | Zymeworks is a global clinical-stage ...See details»
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and …
Jan 16, 2024 VANCOUVER, British Columbia, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a …See details»
Zymeworks Inc. - Life Sciences British Columbia
Dec 12, 2024 Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific …See details»
Zymeworks Inc. - BioTalent Canada
Zymeworks is a global biotechnology company developing novel, multifunctional therapeutics to address difficult-to-treat cancers and other serious diseases. We are driven by our mission to …See details»
Zymeworks - The Org
Zymeworks (NYSE:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics.See details»
Zymeworks Provides Corporate Update and Reports First Quarter …
10 hours ago VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a …See details»
Zymeworks Provides Corporate Update and Reports First
10 hours ago “Our productive R&D organization continues to demonstrate Zymeworks’ ability to generate high-value therapeutic candidates by identifying and advancing novel targets, with …See details»
Our Science - Zymeworks
Zymeworks is an industry leader in multispecific research and the use of this technology in developing therapeutics targeting areas of high unmet medical need. Our clinically validated …See details»
Zymeworks Company Profile - Office Locations, Competitors
Oct 29, 2024 Zymeworks is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases. The Company's approach …See details»
Zymeworks Provides Corporate Update and Reports First Quarter …
1 day ago Zymeworks Inc. Six posters presented at the American Association for Cancer Research (AACR) annual meeting. Appointment of Dr. Sabeen Mekan as Senior Vice …See details»
Zymeworks Inc. - AnnualReports.com
Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric … More â„¢ bispecific antibody currently in a registration-enabling clinical trial for refractory HER2+ biliary …See details»
Zymeworks - Contacts, Employees, Board Members, Advisors
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. ... Experience the new Crunchbase, powered …See details»
Zymeworks Provides Corporate Update and Reports Fourth …
Apr 4, 2025 Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific …See details»
Zymeworks Inc Company Profile - Overview - GlobalData
Zymeworks Inc (Zymeworks) is a clinical-stage biotechnology company that develops novel and multifunctional biotherapeutics. It utilizes Azymetric, Zymelink, EFECT, Protect and T Cell …See details»
Zymeworks Inc. Reports Financial Results and Highlights Recent
Zymeworks announced financial results, appointed Dr. Sabeen Mekan, and presented six posters at AACR 2025. ... “Our productive R&D organization continues to demonstrate Zymeworks’ …See details»
Zymeworks Layoffs: Your Rights and Severance Pay Explained
Apr 14, 2025 Zymeworks is a Canadian biotechnology company headquartered in Vancouver, British Columbia. Founded in 2003, the company focuses on the development of antibody …See details»